GameChangers: The Frequent Use of Digoxin

GameChangers: The Frequent Use of Digoxin

One of the oldest medications in our pharmacopeia is digoxin. It may be used for atrial fibrillation and heart failure, although not as a first-line agent. Despite this, digoxin use is on the rise. Join host, Geoff Wall, as he evaluates why more prescribers are using digoxin.

THE GAMECHANGER: No new randomized controlled trials have been published to justify the increased use of digoxin. However, when used, providers should routinely monitor digoxin levels.

Upon successful completion of this course, learners should be able to:
1. Apply information on the potential uses and harms of digoxin
2. Apply a strategy for monitoring digoxin in heart failure patients

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: December 18, 2023
Planned Expiration Date: December 18, 2024

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-23-400-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.